Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 30, 2013

View Archived Issues

ADAM10: potential target and genetic marker for late-onset AD

Discovery of a broad-genotype inhibitor of HCV replication

AllaChem completes phase I study of AV-4025

Hasselt University and Inova Diagnostics collaborate on biomarkers for RA

AstraZeneca selects miRNA oncology target under alliance with Regulus Therapeutics

STADA in-licenses approved biosimilar from Apotex

Santaris resumes full ownership of LNA programs licensed to Enzon

BELLUS Health and AmorChem sign co-development agreement for AL amyloidosis

BioTime discloses interim results from safety study of Renevia

Phase I/II trial of vosaroxin in myelodysplastic syndrome begins

Sophiris begins dosing in PLUS-1 phase III trial of PRX-302

Etanercept biosimilar product meets primary endpoint in pivotal study

Updated clinical data on nintedanib reported

Crown Bioscience describes patient-derived xenografts for testing CBI-3103

Bristol-Myers Squibb reports developments of third quarter 2013

University of South Florida discloses new myricanol derivatives

French team presents novel diagnostics for Alzheimer's disease

Novartis reports progress during third quarter 2013

Polish researchers patent new bacterial efflux pump inhibitors

Researchers at Apac Pharmaceutical synthesize novel agents for arthritis

Pharmacodynamic activity seen for AMG-811 in patients with SLE

Janssen Pharmaceutica divulges new CCR2 receptor antagonists

Stemline Therapeutics to accelerate development of SL-401 in hematologic cancers

Cara Therapeutics reports results from phase II trial of CR-845

Novel osteoporosis mouse models carry human RANKL gene

OncoMed Pharmaceuticals begins phase Ib trial of vantictumab with paclitaxel

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...